229 related articles for article (PubMed ID: 36632791)
21. Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions.
Bogumil H; Sill M; Schrimpf D; Ismer B; Blume C; Rahmanzade R; Hinz F; Cherkezov A; Banan R; Friedel D; Reuss DE; Selt F; Ecker J; Milde T; Pajtler KW; Schittenhelm J; Hench J; Frank S; Boldt HB; Kristensen BW; Scheie D; Melchior LC; Olesen V; Sehested A; Boué DR; Abdullaev Z; Satgunaseelan L; Kurth I; Seidlitz A; White CL; Ng HK; Shi ZF; Haberler C; Deckert M; Timmer M; Goldbrunner R; Tauziède-Espariat A; Varlet P; Brandner S; Alexandrescu S; Snuderl M; Aldape K; Korshunov A; Witt O; Herold-Mende C; Unterberg A; Wick W; Pfister SM; von Deimling A; Jones DTW; Sahm F; Sievers P
Acta Neuropathol; 2023 May; 145(5):667-680. PubMed ID: 36933012
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
[TBL] [Abstract][Full Text] [Related]
23. A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in
Usta D; Sigaud R; Buhl JL; Selt F; Marquardt V; Pauck D; Jansen J; Pusch S; Ecker J; Hielscher T; Vollmer J; Sommerkamp AC; Rubner T; Hargrave D; van Tilburg CM; Pfister SM; Jones DTW; Remke M; Brummer T; Witt O; Milde T
Mol Cancer Ther; 2020 Aug; 19(8):1736-1750. PubMed ID: 32451331
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
Johnson A; Severson E; Gay L; Vergilio JA; Elvin J; Suh J; Daniel S; Covert M; Frampton GM; Hsu S; Lesser GJ; Stogner-Underwood K; Mott RT; Rush SZ; Stanke JJ; Dahiya S; Sun J; Reddy P; Chalmers ZR; Erlich R; Chudnovsky Y; Fabrizio D; Schrock AB; Ali S; Miller V; Stephens PJ; Ross J; Crawford JR; Ramkissoon SH
Oncologist; 2017 Dec; 22(12):1478-1490. PubMed ID: 28912153
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic Fusions in Gliomas: An Institutional Experience.
Polivka J; Svajdler M; Priban V; Mracek J; Kasik P; Martinek P; Ptakova N; Sharif Bagheri M; Shetti D; Pesta M; Potuznik P; Topolcan O
Anticancer Res; 2022 Apr; 42(4):1933-1939. PubMed ID: 35347013
[TBL] [Abstract][Full Text] [Related]
26. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
27. Targeted next generation sequencing of MLH1-deficient, MLH1 promoter hypermethylated, and BRAF/RAS-wild-type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions.
Vaňková B; Vaněček T; Ptáková N; Hájková V; Dušek M; Michal M; Švajdler P; Daum O; Daumová M; Michal M; Mezencev R; Švajdler M
Genes Chromosomes Cancer; 2020 Oct; 59(10):562-568. PubMed ID: 32427409
[TBL] [Abstract][Full Text] [Related]
28. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.
Chakravarty D; Johnson A; Sklar J; Lindeman NI; Moore K; Ganesan S; Lovly CM; Perlmutter J; Gray SW; Hwang J; Lieu C; André F; Azad N; Borad M; Tafe L; Messersmith H; Robson M; Meric-Bernstam F
J Clin Oncol; 2022 Apr; 40(11):1231-1258. PubMed ID: 35175857
[TBL] [Abstract][Full Text] [Related]
29. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
30. Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors.
Patel RR; Ramkissoon SH; Ross J; Weintraub L
Pediatr Blood Cancer; 2020 Jul; 67(7):e28338. PubMed ID: 32386112
[TBL] [Abstract][Full Text] [Related]
31. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
[TBL] [Abstract][Full Text] [Related]
32. What is the Burden of Proof for Tumor Mutational Burden in gliomas?
Khasraw M; Walsh KM; Heimberger AB; Ashley DM
Neuro Oncol; 2020 Nov; 23(1):17-22. PubMed ID: 33252666
[TBL] [Abstract][Full Text] [Related]
33. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
34. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.
Yao TW; Zhang J; Prados M; Weiss WA; James CD; Nicolaides T
Oncotarget; 2015 Sep; 6(26):21993-2005. PubMed ID: 26023796
[TBL] [Abstract][Full Text] [Related]
35. Emerging Biomarkers in Personalized Therapy of Lung Cancer.
Cagle PT; Raparia K; Portier BP
Adv Exp Med Biol; 2016; 890():25-36. PubMed ID: 26703797
[TBL] [Abstract][Full Text] [Related]
36. BRAF V600E mutation is associated with mTOR signaling activation in glioneuronal tumors.
Prabowo AS; Iyer AM; Veersema TJ; Anink JJ; Schouten-van Meeteren AY; Spliet WG; van Rijen PC; Ferrier CH; Capper D; Thom M; Aronica E
Brain Pathol; 2014 Jan; 24(1):52-66. PubMed ID: 23941441
[TBL] [Abstract][Full Text] [Related]
37. Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.
Quéré G; Descourt R; Robinet G; Autret S; Raguenes O; Fercot B; Alemany P; Uguen A; Férec C; Quintin-Roué I; Le Gac G
BMC Cancer; 2016 Mar; 16():210. PubMed ID: 26968843
[TBL] [Abstract][Full Text] [Related]
38. Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults.
Rodriguez FJ; Vizcaino MA; Lin MT
J Mol Diagn; 2016 Sep; 18(5):620-634. PubMed ID: 27444975
[TBL] [Abstract][Full Text] [Related]
39. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
40. The 2021 WHO Classification of Tumors of the Central Nervous System: An update on pediatric low-grade gliomas and glioneuronal tumors.
Bale TA; Rosenblum MK
Brain Pathol; 2022 Jul; 32(4):e13060. PubMed ID: 35218102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
